|Articles|July 15, 2002
- BioPharm International-07-01-2002
- Volume 15
- Issue 7
Inside Washington: One Hundred Years of Biotech Regulation
Author(s)Jill Wechsler
by Jill Wechsler, CBER is heralding its rich regulatory history while preparing to tackle new scientific and administrative challenges.
Advertisement
Articles in this issue
about 23 years ago
Facilitating Client Audits: The Contract Laboratory Perspectiveabout 23 years ago
Knowledge Management: The Four Pillars of Successabout 23 years ago
Guest Editorial: Supreme Court Rules on FestoNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
